Neural	neural	O	O	O	O
correlates	correlates	O	O	O	O
of	of	O	O	O	O
S-ketamine	s-ketamine	O	O	O	O
induced	induced	O	O	O	O
psychosis	psychosis	O	DISEASE	OTHERS	I
during	during	O	O	O	O
overt	overt	O	O	O	O
continuous	continuous	O	O	O	O
verbal	verbal	O	O	O	O
fluency	fluency	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
glutamatergic	glutamatergic	O	O	O	O
N-methyl-D-aspartate	n-methyl-d-aspartate	O	O	O	O
(	(	O	O	O	O
NMDA	nmda	CHEMICALS	O	OTHERS	I
)	)	O	O	O	O
receptor	receptor	O	O	O	O
has	has	O	O	O	O
been	been	O	O	O	O
implicated	implicated	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
pathophysiology	pathophysiology	O	O	O	O
of	of	O	O	O	O
schizophrenia	schizophrenia	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Administered	administered	O	O	O	O
to	to	O	O	O	O
healthy	healthy	O	O	O	O
volunteers	volunteers	O	O	O	O
,	,	O	O	O	O
a	a	O	O	O	O
subanesthetic	subanesthetic	O	O	O	O
dose	dose	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
non-competitive	non-competitive	O	O	O	O
NMDA	nmda	CHEMICALS	O	OTHERS	I
receptor	receptor	O	O	O	O
antagonist	antagonist	O	O	O	O
ketamine	ketamine	CHEMICALS	O	OTHERS	I
leads	leads	O	O	O	O
to	to	O	O	O	O
psychopathological	psychopathological	O	O	O	O
symptoms	symptoms	O	O	O	O
similar	similar	O	O	O	O
to	to	O	O	O	O
those	those	O	O	O	O
observed	observed	O	O	O	O
in	in	O	O	O	O
schizophrenia	schizophrenia	O	DISEASE	OTHERS	I
.	.	O	O	O	O

In	in	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
schizophrenia	schizophrenia	O	DISEASE	OTHERS	I
,	,	O	O	O	O
ketamine	ketamine	CHEMICALS	O	OTHERS	I
exacerbates	exacerbates	O	O	O	O
the	the	O	O	O	O
core	core	O	O	O	O
symptoms	symptoms	O	O	O	O
of	of	O	O	O	O
illness	illness	O	O	O	O
,	,	O	O	O	O
supporting	supporting	O	O	O	O
the	the	O	O	O	O
hypothesis	hypothesis	O	O	O	O
of	of	O	O	O	O
a	a	O	O	O	O
glutamatergic	glutamatergic	O	O	OTHERS	I
dysfunction	dysfunction	O	O	OTHERS	I
.	.	O	O	O	O

In	in	O	O	O	O
a	a	O	O	O	O
counterbalanced	counterbalanced	O	O	O	O
,	,	O	O	O	O
placebo-controlled	placebo-controlled	O	O	O	O
,	,	O	O	O	O
double-blind	double-blind	O	O	O	O
study	study	O	O	O	O
design	design	O	O	O	O
,	,	O	O	O	O
healthy	healthy	O	O	O	O
subjects	subjects	O	O	O	O
were	were	O	O	O	O
administered	administered	O	O	O	O
a	a	O	O	O	O
continuous	continuous	O	O	O	O
subanesthetic	subanesthetic	O	O	O	O
S-ketamine	s-ketamine	O	O	O	O
infusion	infusion	O	O	O	O
while	while	O	O	O	O
differences	differences	O	O	O	O
in	in	O	O	O	O
BOLD	bold	O	O	O	O
responses	responses	O	O	O	O
measured	measured	O	O	O	O
with	with	O	O	O	O
fMRI	fmri	O	O	O	O
were	were	O	O	O	O
detected	detected	O	O	O	O
.	.	O	O	O	O

During	during	O	O	O	O
the	the	O	O	O	O
scanning	scanning	O	O	O	O
period	period	O	O	O	O
,	,	O	O	O	O
subjects	subjects	O	O	O	O
performed	performed	O	O	O	O
continuous	continuous	O	O	O	O
overt	overt	O	O	O	O
verbal	verbal	O	O	O	O
fluency	fluency	O	O	O	O
tasks	tasks	O	O	O	O
(	(	O	O	O	O
phonological	phonological	O	O	O	O
,	,	O	O	O	O
lexical	lexical	O	O	O	O
and	and	O	O	O	O
semantic	semantic	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Ketamine-induced	ketamine-induced	O	O	O	O
psychopathological	psychopathological	O	O	O	O
symptoms	symptoms	O	O	O	O
were	were	O	O	O	O
assessed	assessed	O	O	O	O
with	with	O	O	O	O
the	the	O	O	O	O
Positive	positive	O	O	O	O
and	and	O	O	O	O
Negative	negative	O	O	O	O
Syndrome	syndrome	O	O	O	O
Scale	scale	O	O	O	O
(	(	O	O	O	O
PANSS	panss	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Ketamine	ketamine	CHEMICALS	O	OTHERS	I
elicited	elicited	O	O	O	O
psychosis	psychosis	O	DISEASE	OTHERS	I
like	like	O	O	O	O
psychopathology	psychopathology	O	O	O	O
.	.	O	O	O	O

Post-hoc	post-hoc	O	O	O	O
t-tests	t-tests	O	O	O	O
revealed	revealed	O	O	O	O
significant	significant	O	O	O	O
differences	differences	O	O	O	O
between	between	O	O	O	O
placebo	placebo	O	O	O	O
and	and	O	O	O	O
ketamine	ketamine	CHEMICALS	O	OTHERS	I
for	for	O	O	O	O
the	the	O	O	O	O
amounts	amounts	O	O	O	O
of	of	O	O	O	O
words	words	O	O	O	O
generated	generated	O	O	O	O
during	during	O	O	O	O
lexical	lexical	O	O	O	O
and	and	O	O	O	O
semantic	semantic	O	O	O	O
verbal	verbal	O	O	O	O
fluency	fluency	O	O	O	O
,	,	O	O	O	O
while	while	O	O	O	O
the	the	O	O	O	O
phonological	phonological	O	O	O	O
domain	domain	O	O	O	O
remained	remained	O	O	O	O
unaffected	unaffected	O	O	O	O
.	.	O	O	O	O

Ketamine	ketamine	CHEMICALS	O	OTHERS	I
led	led	O	O	O	O
to	to	O	O	O	O
enhanced	enhanced	O	O	O	O
cortical	cortical	O	O	O	O
activations	activations	O	O	O	O
in	in	O	O	O	O
supramarginal	supramarginal	O	O	O	O
and	and	O	O	O	O
frontal	frontal	O	O	O	O
brain	brain	O	O	O	O
regions	regions	O	O	O	O
for	for	O	O	O	O
phonological	phonological	O	O	O	O
and	and	O	O	O	O
lexical	lexical	O	O	O	O
verbal	verbal	O	O	O	O
fluency	fluency	O	O	O	O
,	,	O	O	O	O
but	but	O	O	O	O
not	not	O	O	O	O
for	for	O	O	O	O
semantic	semantic	O	O	O	O
verbal	verbal	O	O	O	O
fluency	fluency	O	O	O	O
.	.	O	O	O	O

Ketamine	ketamine	CHEMICALS	O	OTHERS	I
induces	induces	O	O	O	O
activation	activation	O	O	O	O
changes	changes	O	O	O	O
in	in	O	O	O	O
healthy	healthy	O	O	O	O
subjects	subjects	O	O	O	O
similar	similar	O	O	O	O
to	to	O	O	O	O
those	those	O	O	O	O
observed	observed	O	O	O	O
in	in	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
schizophrenia	schizophrenia	O	DISEASE	OTHERS	I
,	,	O	O	O	O
particularly	particularly	O	O	O	O
in	in	O	O	O	O
frontal	frontal	O	O	O	O
and	and	O	O	O	O
temporal	temporal	O	O	O	O
brain	brain	O	O	O	O
regions	regions	O	O	O	O
.	.	O	O	O	O

Our	our	O	O	O	O
results	results	O	O	O	O
provide	provide	O	O	O	O
further	further	O	O	O	O
support	support	O	O	O	O
for	for	O	O	O	O
the	the	O	O	O	O
hypothesis	hypothesis	O	O	O	O
of	of	O	O	O	O
an	an	O	O	O	O
NMDA	nmda	CHEMICALS	O	OTHERS	I
receptor	receptor	O	O	O	O
dysfunction	dysfunction	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
pathophysiology	pathophysiology	O	O	O	O
of	of	O	O	O	O
schizophrenia	schizophrenia	O	DISEASE	OTHERS	I
.	.	O	O	O	O

